US 11,679,159 B2
Compositions for transfecting resistant cell types
Anitha Thomas, New Westminster (CA); Andrew William Brown, Vancouver (CA); Rebecca Anne Grace De Souza, Vancouver (CA); and Tara L. Fernandez, Vancouver (CA)
Assigned to Precision Nanosystems ULC, Vancouver (CA)
Appl. No. 17/51,572
Filed by Precision Nanosystems ULC, Vancouver (CA)
PCT Filed Apr. 15, 2019, PCT No. PCT/CA2019/050456
§ 371(c)(1), (2) Date Oct. 29, 2020,
PCT Pub. No. WO2019/210394, PCT Pub. Date Nov. 7, 2019.
Claims priority of provisional application 62/664,208, filed on Apr. 29, 2018.
Prior Publication US 2021/0162052 A1, Jun. 3, 2021
Int. Cl. A61K 47/28 (2006.01); A61K 47/26 (2006.01); A61K 48/00 (2006.01)
CPC A61K 47/28 (2013.01) [A61K 47/26 (2013.01); A61K 48/0008 (2013.01)] 19 Claims
 
1. A transfection reagent composition comprising:
35-50 Mol % of a cationic ionizable lipid, or a pharmaceutically acceptable salt thereof;
15 to 25 Mol % structural lipid;
35 to 41 Mol % sterol; and
0.5 to about 10 Mol % of a stabilizing agent, wherein the stabilizing agent is a maltoside and comprises more than one surfactant.